FILE PHOTO: The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai May 22, 2014. REUTERS/Aly Song
(Reuters) – The U.S. Food and Drug Administration approved Roche Holding AG’s personalized cancer treatment, the agency said on Thursday.
The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling. The treatment is used to treat certain types of solid tumors and a type of lung cancer.
Reporting by Aakash Jagadeesh Babu and Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur
Powered by WPeMatico